These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 25473003)
1. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Shou Y; Robinson DM; Amakye DD; Rose KL; Cho YJ; Ligon KL; Sharp T; Haider AS; Bandaru R; Ando Y; Geoerger B; Doz F; Ashley DM; Hargrave DR; Casanova M; Tawbi HA; Rodon J; Thomas AL; Mita AC; MacDonald TJ; Kieran MW Clin Cancer Res; 2015 Feb; 21(3):585-93. PubMed ID: 25473003 [TBL] [Abstract][Full Text] [Related]
2. Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. Kieran MW; Chisholm J; Casanova M; Brandes AA; Aerts I; Bouffet E; Bailey S; Leary S; MacDonald TJ; Mechinaud F; Cohen KJ; Riccardi R; Mason W; Hargrave D; Kalambakas S; Deshpande P; Tai F; Hurh E; Geoerger B Neuro Oncol; 2017 Oct; 19(11):1542-1552. PubMed ID: 28605510 [TBL] [Abstract][Full Text] [Related]
3. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis. Li Y; Song Q; Day BW Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788 [TBL] [Abstract][Full Text] [Related]
4. PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition. Metcalfe C; Alicke B; Crow A; Lamoureux M; Dijkgraaf GJ; Peale F; Gould SE; de Sauvage FJ Cancer Res; 2013 Dec; 73(23):7034-42. PubMed ID: 24154871 [TBL] [Abstract][Full Text] [Related]
5. Phosphoproteomics of short-term hedgehog signaling in human medulloblastoma cells. Scheidt T; Alka O; Gonczarowska-Jorge H; Gruber W; Rathje F; Dell'Aica M; Rurik M; Kohlbacher O; Zahedi RP; Aberger F; Huber CG Cell Commun Signal; 2020 Jun; 18(1):99. PubMed ID: 32576205 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation. Wong H; Alicke B; West KA; Pacheco P; La H; Januario T; Yauch RL; de Sauvage FJ; Gould SE Clin Cancer Res; 2011 Jul; 17(14):4682-92. PubMed ID: 21610148 [TBL] [Abstract][Full Text] [Related]
7. Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma. Gordon RE; Zhang L; Peri S; Kuo YM; Du F; Egleston BL; Ng JMY; Andrews AJ; Astsaturov I; Curran T; Yang ZJ Clin Cancer Res; 2018 Mar; 24(6):1375-1388. PubMed ID: 29437795 [No Abstract] [Full Text] [Related]
11. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Rodon J; Tawbi HA; Thomas AL; Stoller RG; Turtschi CP; Baselga J; Sarantopoulos J; Mahalingam D; Shou Y; Moles MA; Yang L; Granvil C; Hurh E; Rose KL; Amakye DD; Dummer R; Mita AC Clin Cancer Res; 2014 Apr; 20(7):1900-9. PubMed ID: 24523439 [TBL] [Abstract][Full Text] [Related]
12. MK-4101, a Potent Inhibitor of the Hedgehog Pathway, Is Highly Active against Medulloblastoma and Basal Cell Carcinoma. Filocamo G; Brunetti M; Colaceci F; Sasso R; Tanori M; Pasquali E; Alfonsi R; Mancuso M; Saran A; Lahm A; Di Marcotullio L; Steinkühler C; Pazzaglia S Mol Cancer Ther; 2016 Jun; 15(6):1177-89. PubMed ID: 26960983 [TBL] [Abstract][Full Text] [Related]
13. RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via JNK-dependent but p53-independent mechanism. Azatyan A; Gallo-Oller G; Diao Y; Selivanova G; Johnsen JI; Zaphiropoulos PG Cancer Lett; 2019 Feb; 442():341-350. PubMed ID: 30447254 [TBL] [Abstract][Full Text] [Related]
14. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma. Faria CC; Golbourn BJ; Dubuc AM; Remke M; Diaz RJ; Agnihotri S; Luck A; Sabha N; Olsen S; Wu X; Garzia L; Ramaswamy V; Mack SC; Wang X; Leadley M; Reynaud D; Ermini L; Post M; Northcott PA; Pfister SM; Croul SE; Kool M; Korshunov A; Smith CA; Taylor MD; Rutka JT Cancer Res; 2015 Jan; 75(1):134-46. PubMed ID: 25391241 [TBL] [Abstract][Full Text] [Related]
15. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway. Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899 [TBL] [Abstract][Full Text] [Related]
16. Prostaglandin E1 Inhibits Wu F; Zhang C; Zhao C; Wu H; Teng Z; Jiang T; Wang Y Cancer Res; 2020 Jul; 80(13):2818-2832. PubMed ID: 32371475 [TBL] [Abstract][Full Text] [Related]
17. Medulloblastoma molecular dissection: the way toward targeted therapy. Remke M; Ramaswamy V; Taylor MD Curr Opin Oncol; 2013 Nov; 25(6):674-81. PubMed ID: 24076581 [TBL] [Abstract][Full Text] [Related]
18. Identification of pseudolaric acid B as a novel Hedgehog pathway inhibitor in medulloblastoma. Wei SF; He DH; Zhang SB; Lu Y; Ye X; Fan XZ; Wang H; Wang Q; Liu YQ Biochem Pharmacol; 2021 Aug; 190():114593. PubMed ID: 33964282 [TBL] [Abstract][Full Text] [Related]
19. AT-101 inhibits hedgehog pathway activity and cancer growth. Wang J; Peng Y; Liu Y; Yang J; Huang M; Tan W Cancer Chemother Pharmacol; 2015 Sep; 76(3):461-9. PubMed ID: 26113054 [TBL] [Abstract][Full Text] [Related]
20. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. Rudin CM; Hann CL; Laterra J; Yauch RL; Callahan CA; Fu L; Holcomb T; Stinson J; Gould SE; Coleman B; LoRusso PM; Von Hoff DD; de Sauvage FJ; Low JA N Engl J Med; 2009 Sep; 361(12):1173-8. PubMed ID: 19726761 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]